Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$9.60
-0.03-0.31%
At close: -
$9.60
0.000.00%
After Hours: 4:04 PM EDT
Comments
Loading...
Evolent Health Analyst Ratings and Price Targets | NYSE:EVH | Benzinga
Evolent Health Inc has a consensus price target of $24.1 based on the ratings of 20 analysts. The high is $59 issued by Cowen & Co. on January 30, 2023. The low is $12 issued by JP Morgan on March 10, 2025. The 3 most-recent analyst ratings were released by JP Morgan, Citizens Capital Markets, and Piper Sandler on March 10, 2025, February 24, 2025, and February 21, 2025, respectively. With an average price target of $13.67 between JP Morgan, Citizens Capital Markets, and Piper Sandler, there's an implied 42.36% upside for Evolent Health Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
Citizens Capital Markets
Piper Sandler
Needham
JMP Securities
1calculated from analyst ratings
Analyst Ratings for Evolent Health
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/10/2025 | Buy Now | 25% | JP Morgan | Anne Samuel55% | $13 → $12 | Maintains | Overweight | Get Alert |
| 02/24/2025 | Buy Now | 35.42% | Citizens Capital Markets | Constantine Davides38% | $13 → $12 | Maintains | Market Outperform | Get Alert |
| 02/21/2025 | Buy Now | 66.67% | Piper Sandler | Jessica Tassan40% | $17 → $16 | Reiterates | Overweight → Overweight | Get Alert |
| 02/21/2025 | Buy Now | 56.25% | Needham | Ryan MacDonald59% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 02/14/2025 | Buy Now | 25% | JMP Securities | Constantine Davides38% | $12 → $12 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/12/2025 | Buy Now | 56.25% | Needham | Ryan MacDonald59% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 01/28/2025 | Buy Now | 35.42% | JP Morgan | Anne Samuel55% | $15 → $13 | Maintains | Overweight | Get Alert |
| 01/24/2025 | Buy Now | 87.5% | Oppenheimer | Jeff Jones33% | $28 → $18 | Maintains | Outperform | Get Alert |
| 01/23/2025 | Buy Now | 66.67% | Canaccord Genuity | Richard Close47% | $23 → $16 | Maintains | Buy | Get Alert |
| 01/22/2025 | Buy Now | 56.25% | Truist Securities | Jailendra Singh38% | $20 → $15 | Maintains | Buy | Get Alert |
| 01/21/2025 | Buy Now | 25% | Stephens & Co. | Jeff Garro37% | $16 → $12 | Maintains | Equal-Weight | Get Alert |
| 01/16/2025 | Buy Now | 45.83% | UBS | Kevin Caliendo71% | $27 → $14 | Maintains | Buy | Get Alert |
| 01/15/2025 | Buy Now | 56.25% | Needham | Ryan MacDonald59% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 01/14/2025 | Buy Now | 77.08% | RBC Capital | Sean Dodge49% | $20 → $17 | Maintains | Outperform | Get Alert |
| 01/13/2025 | Buy Now | 108.33% | Truist Securities | Jailendra Singh38% | $24 → $20 | Maintains | Buy | Get Alert |
| 01/10/2025 | Buy Now | 87.5% | Citigroup | Daniel Grosslight43% | $21 → $18 | Maintains | Buy | Get Alert |
| 01/10/2025 | Buy Now | 87.5% | JMP Securities | Constantine Davides38% | $27 → $18 | Maintains | Market Outperform | Get Alert |
| 01/10/2025 | Buy Now | 56.25% | Needham | Matthew Sheerin70% | → $15 | Initiates | → Buy | Get Alert |
| 11/22/2024 | Buy Now | 56.25% | JP Morgan | Anne Samuel55% | $45 → $15 | Maintains | Overweight | Get Alert |
| 11/18/2024 | Buy Now | 191.67% | Oppenheimer | Jeff Jones33% | $34 → $28 | Maintains | Outperform | Get Alert |
| 11/13/2024 | Buy Now | 118.75% | Citigroup | Daniel Grosslight43% | $33 → $21 | Maintains | Buy | Get Alert |
| 11/12/2024 | Buy Now | 108.33% | RBC Capital | Sean Dodge49% | $20 → $20 | Reiterates | Outperform → Outperform | Get Alert |
| 11/11/2024 | Buy Now | 97.92% | Barclays | Stephanie Davis40% | $39 → $19 | Maintains | Overweight | Get Alert |
| 11/08/2024 | Buy Now | 254.17% | Oppenheimer | Jeff Jones33% | $45 → $34 | Maintains | Outperform | Get Alert |
| 11/08/2024 | Buy Now | 66.67% | Stephens & Co. | Jeff Garro37% | → $16 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 10/29/2024 | Buy Now | 243.75% | Citigroup | Daniel Grosslight43% | $35 → $33 | Maintains | Buy | Get Alert |
| 10/11/2024 | Buy Now | 264.58% | Keybanc | Matthew Gillmor65% | → $35 | Initiates | → Overweight | Get Alert |
| 10/08/2024 | Buy Now | 337.5% | RBC Capital | Sean Dodge49% | $42 → $42 | Reiterates | Outperform → Outperform | Get Alert |
| 08/27/2024 | Buy Now | 243.75% | Truist Securities | Jailendra Singh38% | $33 → $33 | Maintains | Buy | Get Alert |
| 08/26/2024 | Buy Now | 337.5% | RBC Capital | Sean Dodge49% | $42 → $42 | Reiterates | Outperform → Outperform | Get Alert |
| 08/19/2024 | Buy Now | 368.75% | JP Morgan | Anne Samuel55% | $36 → $45 | Maintains | Overweight | Get Alert |
| 08/09/2024 | Buy Now | 222.92% | JMP Securities | Constantine Davides38% | $34 → $31 | Maintains | Market Outperform | Get Alert |
| 08/09/2024 | Buy Now | 243.75% | Truist Securities | Jailendra Singh38% | $28 → $33 | Upgrade | Hold → Buy | Get Alert |
| 07/30/2024 | Buy Now | 337.5% | Stephens & Co. | Jeff Garro37% | $42 → $42 | Reiterates | Overweight → Overweight | Get Alert |
| 05/10/2024 | Buy Now | 327.08% | Canaccord Genuity | Richard Close47% | $44 → $41 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | 254.17% | JMP Securities | Constantine Davides38% | $38 → $34 | Maintains | Market Outperform | Get Alert |
| 04/22/2024 | Buy Now | 316.67% | Citigroup | Daniel Grosslight43% | → $40 | Initiates | → Buy | Get Alert |
| 03/28/2024 | Buy Now | 358.33% | Canaccord Genuity | Richard Close47% | $45 → $44 | Maintains | Buy | Get Alert |
| 03/15/2024 | Buy Now | 441.67% | JP Morgan | Anne Samuel55% | $53 → $52 | Maintains | Overweight | Get Alert |
| 03/01/2024 | Buy Now | 368.75% | Oppenheimer | Jeff Jones33% | → $45 | Initiates | → Outperform | Get Alert |
| 02/23/2024 | Buy Now | 295.83% | JMP Securities | Constantine Davides38% | $37 → $38 | Maintains | Market Outperform | Get Alert |
| 02/23/2024 | Buy Now | 368.75% | Canaccord Genuity | Richard Close47% | $47 → $45 | Maintains | Buy | Get Alert |
| 12/06/2023 | Buy Now | 285.42% | JMP Securities | Constantine Davides38% | → $37 | Initiates | → Market Outperform | Get Alert |
| 11/28/2023 | Buy Now | 337.5% | RBC Capital | Sean Dodge49% | $44 → $42 | Maintains | Outperform | Get Alert |
| 11/14/2023 | Buy Now | 254.17% | Truist Securities | Sandy Draper72% | $36 → $34 | Maintains | Hold | Get Alert |
| 10/16/2023 | Buy Now | 379.17% | UBS | Kevin Caliendo71% | → $46 | Initiates | → Buy | Get Alert |
| 08/14/2023 | Buy Now | 389.58% | Guggenheim | Sandy Draper72% | → $47 | Reiterates | Buy → Buy | Get Alert |
| 06/26/2023 | Buy Now | 389.58% | Guggenheim | Sandy Draper72% | $50 → $47 | Maintains | Buy | Get Alert |
| 05/24/2023 | Buy Now | 358.33% | RBC Capital | Sean Dodge49% | → $44 | Reiterates | → Outperform | Get Alert |
| 05/04/2023 | Buy Now | 316.67% | Stephens & Co. | Jeff Garro37% | → $40 | Reiterates | → Overweight | Get Alert |
| 04/12/2023 | Buy Now | 316.67% | Stephens & Co. | Jeff Garro37% | → $40 | Initiates | → Overweight | Get Alert |
| 02/23/2023 | Buy Now | 358.33% | RBC Capital | Sean Dodge49% | → $44 | Reiterates | → Outperform | Get Alert |
| 01/30/2023 | Buy Now | 514.58% | Cowen & Co. | Charles Ryhee50% | $57 → $59 | Maintains | Outperform | Get Alert |
| 11/18/2022 | Buy Now | 493.75% | Cowen & Co. | Charles Ryhee50% | $52 → $57 | Maintains | Outperform | Get Alert |
| 11/04/2022 | Buy Now | 243.75% | Piper Sandler | Jessica Tassan40% | $40 → $33 | Maintains | Overweight | Get Alert |
| 11/01/2022 | Buy Now | 243.75% | Truist Securities | Sandy Draper72% | → $33 | Initiates | → Hold | Get Alert |
| 10/12/2022 | Buy Now | 400% | Canaccord Genuity | Richard Close47% | $55 → $48 | Maintains | Buy | Get Alert |
| 10/12/2022 | Buy Now | 368.75% | BTIG | David Larsen44% | $55 → $45 | Maintains | Buy | Get Alert |
| 08/19/2022 | Buy Now | 441.67% | JP Morgan | Anne Samuel55% | $37 → $52 | Maintains | Overweight | Get Alert |
| 08/03/2022 | Buy Now | 358.33% | RBC Capital | Sean Dodge49% | $40 → $44 | Maintains | Outperform | Get Alert |
| 08/03/2022 | Buy Now | 420.83% | BTIG | David Larsen44% | $45 → $50 | Maintains | Buy | Get Alert |
| 08/03/2022 | Buy Now | 316.67% | Piper Sandler | Jessica Tassan40% | $35 → $40 | Maintains | Overweight | Get Alert |
| 07/29/2022 | Buy Now | 316.67% | RBC Capital | Sean Dodge49% | → $40 | Initiates | → Outperform | Get Alert |
| 06/21/2022 | Buy Now | 420.83% | Cowen & Co. | Charles Rhyee37% | $48 → $50 | Maintains | Outperform | Get Alert |
| 05/09/2022 | Buy Now | 368.75% | Canaccord Genuity | Richard Close47% | $40 → $45 | Maintains | Buy | Get Alert |
| 03/30/2022 | Buy Now | 347.92% | Guggenheim | Sandy Draper72% | → $43 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Evolent Health (EVH) stock?
The latest price target for Evolent Health (NYSE:EVH) was reported by JP Morgan on March 10, 2025. The analyst firm set a price target for $12.00 expecting EVH to rise to within 12 months (a possible 25.00% upside). 37 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Evolent Health (EVH)?
The latest analyst rating for Evolent Health (NYSE:EVH) was provided by JP Morgan, and Evolent Health maintained their overweight rating.
When was the last upgrade for Evolent Health (EVH)?
The last upgrade for Evolent Health Inc happened on August 9, 2024 when Truist Securities raised their price target to $33. Truist Securities previously had a hold for Evolent Health Inc.
When was the last downgrade for Evolent Health (EVH)?
The last downgrade for Evolent Health Inc happened on November 8, 2024 when Stephens & Co. changed their price target from N/A to $16 for Evolent Health Inc.
When is the next analyst rating going to be posted or updated for Evolent Health (EVH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evolent Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evolent Health was filed on March 10, 2025 so you should expect the next rating to be made available sometime around March 10, 2026.
Is the Analyst Rating Evolent Health (EVH) correct?
While ratings are subjective and will change, the latest Evolent Health (EVH) rating was a maintained with a price target of $13.00 to $12.00. The current price Evolent Health (EVH) is trading at is $9.60, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.